1. Udagawa N, Koide M, Nakamura M, et al. Osteoclastdifferentiation by RANKL and OPG signaling pathways. J BoneMiner Metab. 2021;39(1):19-26. doi:10.1007/s00774-020-01162-6
2. Nakamura M, Udagawa N, Matsuura S, et al. Osteoprotegerinregulates bone formation through a coupling mechanism withbone resorption. Endocrinology. 2003;144(12):5441-5449.doi:10.1210/en.2003-0717
3. Solmaz I, Ozdemir MA, Unal E, Abdurrezzak U, MuhtarogluS, Karakukcu M. Effect of vitamin K2 and vitamin D3 onbone mineral density in children with acute lymphoblasticleukemia: a prospective cohort study. J Pediatr Endocrinol Metab.2021;34(4):441-447. doi:10.1515/jpem-2020-0637
4. Pillai PM, Carroll WL. Acute lymphoblastic leukemia. In:Lanzkowsky 7th Edition. United Kingdom. pp:413-437.
5. İçöz K, Gerçek T, Murat A, Özcan S, Ünal E. Capturing B typeacute lymphoblastic leukemia cells using two types of antibodies.Biotechnol Prog. 2019;35(1):e2737. doi:10.1002/btpr.2737
6. Gök V, Özcan A, Yılmaz E, et al. The significance of solubleCD40 and CD40 ligand levels in childhood acute lymphoblasticleukemia patients. J Transl Pract Med. 2022; 1(2); 49-56.
7. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia inchildren. N Engl J Med. 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972
8. Unal E, Caliskan U, Koksal Y. The importance of cystatin-Cfor predicting nephrotoxicity in children with acute leukemiaand non-Hodgkin lymphoma. UHOD-Uluslararası HematolojiOnkoloji Derg./Int J Hematol Oncol. 2009;19:69-74.
9. Halton J, Gaboury I, Grant R, et al. Advanced vertebral fractureamong newly diagnosed children with acute lymphoblasticleukemia: results of the Canadian Steroid-AssociatedOsteoporosis in the Pediatric Population (STOPP) researchprogram. J Bone Miner Res. 2009;24(7):1326-1334. doi:10.1359/jbmr.090202
10. Alos N, Grant RM, Ramsay T, et al. High incidence of vertebralfractures in children with acute lymphoblastic leukemia12 months after the initiation of therapy. J Clin Oncol.2012;30(22):2760-2767. doi:10.1200/JCO.2011.40.4830
11. Angsubhakorn N, Suvannasankha A. Acute lymphoblasticleukaemia with osteolytic bone lesions: diagnostic dilemma.BMJ Case Rep. 2018;2018:bcr2018225008. doi:10.1136/bcr-2018-225008
12. Nagasawa T. Microenvironmental niches in the bonemarrow required for B-cell development. Nat Rev Immunol.2006;6(2):107-116. doi:10.1038/nri1780
13. Rajakumar SA, Papp E, Lee KK, et al. B cell acute lymphoblasticleukemia cells mediate RANK-RANKL-dependent bonedestruction. Sci Transl Med. 2020;12(561):eaba5942. doi:10.1126/scitranslmed.aba5942
14. Dougall WC. Molecular pathways: osteoclast-dependent andosteoclast-independent roles of the RANKL/RANK/OPGpathway in tumorigenesis and metastasis. Clin Cancer Res.2012;18(2):326-335. doi:10.1158/1078-0432.CCR-10-2507
15. Roodman GD, Dougall WC. RANK ligand as a therapeutic targetfor bone metastases and multiple myeloma. Cancer Treat Rev.2008;34(1):92-101. doi:10.1016/j.ctrv.2007.09.002
16. Rajakumar SA, Danska JS. Bad to the bone: B cell acutelymphoblastic leukemia cells mediate bone destruction. Mol CellOncol. 2020;8(1):1835423. doi:10.1080/23723556.2020.1835423